Innovative Clinical Stage ENYO Pharma is a clinical-stage biotechnology company focusing on developing therapeutics for kidney-related diseases, which indicates potential for partnerships in clinical research, trial management, and early-stage biotech service providers.
Recent Funding Success With a recent €36 million Series C funding round and $47 million in total funding, ENYO Pharma demonstrates strong investor confidence, suggesting they are prepared to invest in new collaborations, technology solutions, and supply chain partnerships to accelerate development.
Strategic Partnerships The company's recent partnership with Vesalius Biocapital for clinical studies highlights an openness to external collaborations, providing opportunities for co-development, licensing, and strategic alliances within the biotech and pharmaceutical sectors.
Recognition and Growth Being listed in the Top 50 of the EIC ScalingUp list signals rapid growth and innovation capability, making ENYO Pharma a potential client for growth-focused technology and consulting services aimed at expanding biotech operations.
Targeted Therapeutic Niche Specializing in fibrosis and anti-inflammatory therapeutics for kidney diseases, ENYO Pharma has a focused market segment that could benefit from tailored biotech tools, contract research organizations, and specialized pharmaceutical services to support their Phase 2 trials.
ENYO Pharma uses 8 technology products and services including Google Hosted Libraries, jQuery CDN, Open Graph, and more. Explore ENYO Pharma's tech stack below.
| ENYO Pharma Email Formats | Percentage |
| FL@enyopharma.com | 51% |
| First.Last@enyopharma.com | 38% |
| Last@enyopharma.com | 6% |
| FirstLast@enyopharma.com | 5% |
Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees
ENYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome.
Company Overview
Funding & FinancialsENYO Pharma has raised a total of $47M of funding over 1 rounds. Their latest funding round was raised on Apr 06, 2018 in the amount of $47Mas a Series B.
ENYO Pharma's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsENYO Pharma has raised a total of $47M of funding over 1 rounds. Their latest funding round was raised on Apr 06, 2018 in the amount of $47Mas a Series B.
ENYO Pharma's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com